Binnopharm Group has reinforced its position in international markets: 68 new marketing authorisations in 2024

In 2024, Binnopharm Group received 68 marketing authorisations (MA) for 22 medicinal products. The documents were approved in 11 countries: Azerbaijan, Armenia, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Mongolia, Transdniestria (MTR), Tajikistan and Uzbekistan. All registration procedures comply with the requirements of the EAEU and national standards, covering both prescription and over-the-counter medicines in various therapeutic areas.

The company’s export revenue shows a stable growth; according to the results of 2024, it reached 3.8 billion rubles. The main contribution to this growth was made by key markets, such as Kazakhstan, Kyrgyzstan and Uzbekistan, where the volume of deliveries increased by 30%. This has been made possible due to new medicines successful registration and the portfolio expansion, as well as an active promotion and cooperation with the medical community.

In addition to receiving new MAs, Binnopharm Group maintained more than 300 marketing authorisations up to date. This included extending validity periods, adding new manufacturers of substances and packaging materials, as well as updating instructions. This work ensured continuity of supplies and reduced the risks associated with the regulatory requirements amendments.

International expansion remains a priority for Binnopharm Group. In 2023, the company successfully entered the Chinese market, creating a local structure for cooperation with local partners. In December 2024, Binnopharm Group announced preparations for entry to the Iraqi market, where the first supplies were planned for the fourth quarter of 2025. Moreover, in January 2025, the company established its representative office in Vietnam to expand its commercial presence in international markets.